Long-Term Real-Life Experience With Rituximab in Adult Finnish Patients With Rheumatoid Arthritis Refractory or With Contraindication to Anti-Tumor Necrosis Factor Drugs



: Valleala H, Korpela M, Hienonen-Kempas T, Immonen K, Lahteenmaki J, Uusitalo T, Komulainen R, Mottonen T, Hannonen P

Publisher: LIPPINCOTT WILLIAMS & WILKINS

: 2015

: JCR: Journal of Clinical Rheumatology

: JCR-JOURNAL OF CLINICAL RHEUMATOLOGY

: JCR-J CLIN RHEUMATOL

: 21

: 1

: 24

: 30

: 7

: 1076-1608

DOI: https://doi.org/10.1097/RHU.0000000000000166


Conclusions: The treatment as-needed regimen used in this study cohort led to delayed RTX retreatment and disease flare in a significant proportion of patients. A regular retreatment every 6 months, at least, after the first 2 treatment courses in patients who are not in remission could allow better control of disease activity.




Last updated on 2024-26-11 at 14:12